Apotex launches drug to treat relapsing remitting multiple sclerosis
by CM Staff
The product adds to Apotex's existing MS product portfolio to three products including APO-Fingolimod™ and APO-Dimethyl Fumarate™.
TORONTO — Apotex Inc., a pharmaceutical manufacturer of generic medicines, announced the Canadian launch of APO-Teriflunomide™ tablets, a generic version of Aubagio®, for the treatment of relapsing remitting multiple sclerosis (RRMS).
Apotex’s teriflunomide is a once-daily monotherapy indicated to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability for patients with RRMS.
“We are pleased to provide Canada’s multiple sclerosis patient community with a generic option of oral treatment, ” said Raymond Shelley, SVP, Commercial Operations, Canada & Rest of World Markets. “With this launch, patients will gain access to high-quality, Canadian-made medication, at an affordable price.”
The addition of APO-Teriflunomide™ increases Apotex’s existing MS product portfolio to three products including APO-Fingolimod™ and APO-Dimethyl Fumarate™.
Apo-Teriflunomide is part of the ApoAssist® comprehensive patient support program trying to help patients and healthcare professionals with reimbursement navigation, financial assistance for eligible patients, and coverage renewals, in addition to product-specific patient support services.
